Stephen Padilla, 20180523120000
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C), with or without statin therapy, according to a study presented at the Asian Pacific Society of Cardiology Congress 2018 (APSC 2018) in Taipei, Taiwan. Additionally, PCSK9 inhibitor shows comparable safety profile.